Executive SummaryThe alpha-beta blocker, marketed by Glaxo as Trandate and by Schering as Normodyne, has been added to the Medi-Cal formulary, making the drug reimbursable under California's Medicaid plan. Labetalol has been shown to be particularly effective in black hypertensives, a group which has not responded well to traditional beta blockers, according to a Glaxo press release.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.